Idalopirdine

Idalopirdine
Clinical data
ATC code None
Identifiers
Synonyms Lu-AE-58054
CAS Number 467459-31-0 N
ChemSpider 19878969 N
ChEMBL CHEMBL3286580
Chemical and physical data
Formula C20H19F5N2O
Molar mass 398.37 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Idalopirdine (INN) (code names Lu AE58054, SGS-518) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of October 2013 it is in phase III clinical trials.[2]

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.[3] Two further phase III trials are due to report in early 2017.[3]

See also

References


This article is issued from Wikipedia - version of the 9/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.